我要投票 瑞阳在中草药行业中的票数:72
· 外 推 电 报 ·
2025-02-05 18:44:52 星期三

【瑞阳是哪个国家的品牌?】

瑞阳是什么牌子?「瑞阳」是 瑞阳制药有限公司 旗下著名品牌。该品牌发源于山东,由创始人苗得足在1998-03-20期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

瑞阳制药有限公司创建于1966年,是山东省第一家粉针剂生产企业。四十多年来,瑞阳制药有限公司秉承“瑞阳制药,造福四方”的经营宗旨,坚持创新为本、品质至上、内强管理、外树品牌、凝聚精英、开放共赢的经营策略,“忠诚守信,坚韧不拔,吃苦耐劳,创新进取”,从一个备战备荒的三线企业,成长为中国医药三十强企业,2010年公司效益位居全国医药工业企业21位。

公司现有总资产40亿余元,员工4000余人。设有国家级企业技术中心、山东省头孢类原料药工程技术研究中心和国家博士后科研工作站,是国家高新技术企业、国家生物医药产业化骨干企业、全国守合同重信用企业、中国专利山东省明星企业。

公司拥有粉针制剂、原料药、固体制剂和中药制剂等20多个生产车间且全部通过国家药品GMP认证。公司还通过了IS09001、ISO14001和OHS18001国际质量、环境、职业健康安全管理体系认证。公司产品有10大类近400个品种规格,年产粉针(冻干)制剂25亿瓶、固体制剂100亿片/粒、合成无菌原料药2000吨、小容量注射剂3亿支。

持续创新是瑞阳制药不断发展的动力之源。瑞阳制药通过加强产品创新、技术创新、营销创新和管理创新形成了自己的发展特点,取得了较快的发展。公司先后与清华大学、山东大学、沈阳药科大学、天津大学、上海医工院、山东医科院等30多家高校和科研机构建立了常年科研合作关系。分别在公司总部、济南、上海和美国设立了四个研发中心,公司的研发能力和技术水平不断提高。

截止目前,公司先后获得国家科技进步二等奖1项、承担国家新药创新重大专项2项,国家级火炬计划项目3项;获得70余项专利证书、60多个新药证书。其中:注射用美洛西林钠制剂及原料药等7个产品通过了山东省科技成果鉴定,有4项填补国内空白,技术水平达到国际领先水平;新药葛根汤颗粒、厚朴排气合剂被认定为“国家重点新产品”。公司的粉针制剂分装水平、中药提取水平和头孢类原料药合成技术均达到国内领先水平。

瑞阳制药坚持以市场为中心,突出抓好营销工作。目前瑞阳制药拥有一支1000余人的专业营销队伍,160多个办事处遍布全国各大中城市,产品已覆盖全国,并远销德、法、韩等30多个国家。

严密的质保体系是瑞阳制药发展的保障。一直以来,无论外在竞争环境如何变化,瑞阳制药始终以严谨、务实的态度,努力从提高产品质量上下工夫,不断提高产品品质,铸造“瑞阳”品牌。瑞阳制药坚守“质量就是天”的诺言,严格按照《药品管理法》、《药品生产质量管理规范》等法律法规的要求组织生产。拥有专业质量检查、监督人员300多人,具有现代化的质量检验中心和先进的监测手段,还通过了山东省质量技术监督局“测量设备计量体系认证”。公司先后负责起草了美洛西林钠、瓦松栓、厚朴排气合剂等42个新药产品的国家药品标准。2010年9月,被国家卫生部药典委授予《中国药典》2010年版标准研究先进单位。

为提高公司信息化管理水平,自2003年以来,公司在主干为千兆的信息平台之上,先后投资1500多万元实施了ERP(企业资源计划)、BPM(项目流程)、HR(人力资源)管理系统、E-MAIL(电子邮件)系统、TPI信息查询系统、网络视频会议和视频监控系统等计算机局域网综合应用项目。先进管理手段的运用,意味着瑞阳公司已经步入企业管理数字化、决策依据数据化的时代。

瑞阳制药在加快企业发展的同时,关注、关心社会公益事业及社会的发展。每年对贫困地区的捐款、对红十字协会的救灾捐助达数百万元,以实际行动,造福百姓、造福四方。近年来,瑞阳制药先后被认定为“山东省医药行业发展突出贡献企业”、“建国60周年山东省医药行业功勋企业”、“新中国60年山东百家领袖品牌”。

瑞阳制药将一如既往地坚持创新为本、品质至上、内强管理、外树品牌、凝聚精英、开放共赢的经营理念,顺国家大势而为,精心打造瑞阳品牌,实现更高质量的成长。

英文翻译:Ruiyang Pharmaceutical Co., Ltd., founded in 1966, is the first powder injection manufacturer in Shandong Province. Over the past 40 years, Ruiyang Pharmaceutical Co., Ltd. has been adhering to the business tenet of "Ruiyang pharmaceutical, benefit the four sides", adhering to the business strategy of innovation-oriented, quality first, internal strong management, external brand building, cohesion of elites, open and win-win, "loyalty, faithfulness, perseverance, hard work, innovation and enterprising", growing from a third-line enterprise ready for war and famine, to one of the top 30 Chinese pharmaceutical enterprises In 2010, the company's efficiency ranked 21 in the national pharmaceutical industry enterprises. The company has total assets of more than 4 billion yuan and more than 4000 employees. With national enterprise technology center, Shandong cephalosporin API engineering technology research center and National Postdoctoral research workstation, it is a national high-tech enterprise, national biomedical industrialization backbone enterprise, national contract abiding and trustworthy enterprise, and a star enterprise in Shandong Province with Chinese patent. The company has more than 20 production workshops including powder injection preparation, API, solid preparation and traditional Chinese medicine preparation, all of which have passed the GMP certification. The company also passed IS09001, ISO14001 and ohs18001 international quality, environment, occupational health and safety management system certification. The company has 10 categories and nearly 400 specifications, with an annual output of 2.5 billion bottles of powder (freeze-dried) preparations, 10 billion tablets / granules of solid preparations, 2000 tons of synthetic sterile APIs, and 300 million small volume injections. Continuous innovation is the driving force for the continuous development of Ruiyang pharmaceutical. Through strengthening product innovation, technology innovation, marketing innovation and management innovation, Ruiyang pharmaceutical has formed its own development characteristics and achieved rapid development. The company has established a long-term scientific research cooperation relationship with more than 30 universities and scientific research institutions, including Tsinghua University, Shandong University, Shenyang Pharmaceutical University, Tianjin University, Shanghai Institute of medical technology, Shandong Medical College, etc. Four R & D centers have been set up in the company headquarters, Ji'nan, Shanghai and the United States. Up to now, the company has won one second prize of national science and technology progress, two major national new drug innovation projects, three national Torch Program projects, more than 70 patent certificates and more than 60 new drug certificates. Among them, 7 products, such as meloxicillin sodium for injection and APIs, have passed the appraisal of scientific and technological achievements in Shandong Province, 4 of which have filled the gaps in China, and the technical level has reached the international leading level; the new drug Gegen Tang granules and Houpu exhaust mixture have been recognized as "national key new products". The company's powder injection preparation sub packaging level, Chinese medicine extraction level and cephalosporin API synthesis technology have reached the domestic leading level. Ruiyang pharmaceutical insists on taking the market as the center and focuses on the marketing work. At present, Ruiyang pharmaceutical has a professional marketing team of more than 1000 people, more than 160 offices all over the country's large and medium-sized cities, products have covered the country, and are exported to more than 30 countries, such as Germany, France, South Korea, etc. Strict quality assurance system is the guarantee for the development of Ruiyang pharmaceutical. All along, no matter how the external competitive environment changes, Ruiyang pharmaceutical has always been rigorous, pragmatic attitude, and strive to improve product quality, constantly improve product quality, and create "Ruiyang" brand. Ruiyang pharmaceutical adheres to the promise of "quality is heaven", and organizes production in strict accordance with the requirements of laws and regulations such as the drug management law and the drug production quality management standard. With more than 300 professional quality inspection and supervision personnel, modern quality inspection center and advanced monitoring means, it has also passed the "measurement system certification of measuring equipment" of Shandong Provincial Bureau of quality and technical supervision. The company has been responsible for drafting the national drug standards for 42 new drug products, such as mezlocillin sodium, vasone suppository, Houpu exhaust mixture, etc. In September 2010, it was awarded the advanced unit of standard research of 2010 edition of Chinese Pharmacopoeia by the Pharmacopoeia Committee of the Ministry of health. In order to improve the information management level of the company, since 2003, the company has invested more than 15 million yuan to implement ERP (enterprise resource plan), BPM (project process), HR (human resource) management system, e-mail (e-mail) system, TPI information query system, network video conference and video monitoring system and other computer LAN Integrated Systems on the basis of the information platform with the backbone of Gigabit Joint application project. The application of advanced management means means that Ruiyang company has entered the era of digitalization of enterprise management and digitalization of decision-making basis. While accelerating the development of enterprises, Ruiyang pharmaceutical pays attention to and cares about the social public welfare and social development. Every year, donations to poverty-stricken areas and the Red Cross Society for disaster relief amount to millions of yuan, benefiting the people and the Quartet through practical actions. In recent years, Ruiyang pharmaceutical has been recognized as "Shandong Pharmaceutical industry development outstanding contribution enterprise", "Shandong Pharmaceutical Industry meritorious enterprise in the 60th anniversary of the founding of the people's Republic of China", "Shandong top 100 leading brands in the 60 years of new China". Ruiyang pharmaceutical will, as always, adhere to the business philosophy of innovation-oriented, quality first, internal strong management, external brand building, cohesion of elites, open and win-win, follow the general trend of the country, carefully build Ruiyang brand, and achieve higher quality growth.

本文链接: https://www.waitui.com/brand/ee4ad6671.html 联系电话:05333221555

千城特选小程序码

7×24h 快讯

慈星股份:终止筹划购买武汉敏声控股权并配套募资事项,股票明起复牌

36氪获悉,慈星股份公告,公司因筹划发行股份及支付现金购买武汉敏声新技术有限公司控股权并募集配套资金事项,公司股票自2025年1月15日开市时起开始停牌。经交易相关方商讨研究决定终止筹划本次交易事项,公司股票将于2025年2月6日(星期四)开市起复牌。 截至公告日,交易各方未就本次交易具体方案、交易条件达成最终实质性协议。

45分钟前

汇丰控股:昨日耗资约1.76亿港元回购219.76万股公司股份

36氪获悉,汇丰控股公告,公司于2月4日耗资约1.76亿港元回购219.76万股公司股份,每股回购价格79.6港元-80.45港元。

45分钟前

印尼网约车巨头GoTo否认与Grab合并传闻

印尼网约车巨头GoTo当地时间2月4日提交文件,否认同竞争对手Grab的合并传闻。该公司称,“除实施股票回购外,未来12个月内没有任何重大行动计划”。此前有市场消息称,Grab与GoTo最近几周加快协商,认为今年是达成交易的有利时机。两家公司上市后均逐渐朝向取得盈利迈进,但竞争激烈导致价格无法调涨,同时挤压利润空间。据报道,过去几年双方一直在断断续续地协商,合并障碍包括双方之间的分歧,以及两家公司在印尼、新加坡等市场主导地位可能带来的反垄断问题。(界面)

45分钟前

众鑫股份:泰国工厂一车间正式投产,预计2025年完成产量3万吨以上

36氪获悉,众鑫股份公告,公司泰国工厂一车间已顺利安装完毕,并于2025年1月8号开始调试设备并试机生产,2月1日顺利完成试机并正式投产。同时,二车间开始安装设备。公司预计2025年完成产量3万吨以上,2026年完成产量5万吨。此外,公司将根据国际市场的变化情况,决策是否对泰国工厂实施扩产计划。本次试机成功为公司拓展海外业务打下了基础,也验证了新装备的先进性,为今后的装备研发与升级提供了宝贵经验。

45分钟前

杭州银行:2024年净利润169.83亿元,同比增长18.08%

36氪获悉, 杭州银行发布业绩快报,2024年度实现营业收入383.81亿元,同比增长9.61%;归属于上市公司股东的净利润169.83亿元,同比增长18.08%。截至2024年末,公司总资产21125.91亿元,较上年末增长14.73%;贷款总额9374.99亿元,较上年末增长16.16%;存款总额12725.51亿元,较上年末增长21.74%。

45分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询